Innova Biosciences introduces Magnetic Conjugation Kit
Magnetic Conjugation Kit.
New kit enables covalent conjugation of antibodies and proteins to magnetic particles.
Innova Biosciences has launched its Magnetic Conjugation Kit, the newest addition to the company’s range of particle conjugation technologies.
The new kit allows researchers to covalently conjugate antibodies and proteins to 0.5µm magnetic particles without the need for extensive optimization of the conjugation reaction, thereby saving precious antibody or protein. The Magnetic Conjugation Kit is ideal for use in immunoprecipitation experiments, as covalent attachment provides a more stable alternative to non-covalent antibody attachments using traditional Protein A or protein G resin.
The specially treated iron oxide magnetic particles offer an ideal balance between high surface area and fast separation, providing a binding capacity that is twice that of leading competitors, allowing high sensitivity to be achieved with less material and minimizing the risk of non-specific binding.
Nick Gee, CEO and CSO at Innova Biosciences, commented: “This new kit is the second product to be added to Innova’s particles range in 2017, following the launch of the Europium conjugation kit in January. We are constantly looking to develop new innovations to make scientists’ lives easier, and will be launching an additional related product later in the year.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.